Compare FRD & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRD | IPSC |
|---|---|---|
| Founded | 1965 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.2M | 362.5M |
| IPO Year | 1995 | 2021 |
| Metric | FRD | IPSC |
|---|---|---|
| Price | $43.81 | $2.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.25 |
| AVG Volume (30 Days) | 78.8K | ★ 481.8K |
| Earning Date | 06-11-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | N/A | ★ 91.30 |
| EPS | ★ 1.79 | N/A |
| Revenue | ★ $121,157,278.00 | $109,164,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.16 | ★ N/A |
| Revenue Growth | 55.82 | ★ 1556.76 |
| 52 Week Low | $16.55 | $0.44 |
| 52 Week High | $48.77 | $2.97 |
| Indicator | FRD | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 57.00 | 47.47 |
| Support Level | $41.16 | $1.88 |
| Resistance Level | $48.77 | $2.39 |
| Average True Range (ATR) | 2.36 | 0.10 |
| MACD | -0.40 | 0.01 |
| Stochastic Oscillator | 32.98 | 40.28 |
Friedman Industries Inc is a manufacturer and processor of metals and operates in two reportable segments: flat-roll products and tubular products. The flat-roll product segment consists of flat-roll processing facilities located in Hickman, Arkansas; Decatur, Alabama; Miami, Florida; East Chicago, Indiana; Granite City, Illinois and Sinton, Texas and a flat-roll distribution facility located in Orlando, Florida. The tubular product segment consists of the Company's Texas Tubular Products division (TTP) located in Lone Star, Texas. TTP operates two electric resistance welded pipe mills with a combined outside diameter (OD). Its products are flat-roll products and tubular products.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.